Steven Cohen Bio Atla, Inc. Call Options Transaction History
Point72 Asset Management, L.P.
- $42.2 Billion
- Q4 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding BCAB
# of Institutions
70Shares Held
23.4MCall Options Held
30.8KPut Options Held
57K-
Anson Funds Management LP Dallas, TX4.6MShares$1.7 Million0.35% of portfolio
-
Acorn Capital Advisors, LLC New York, NY4.03MShares$1.49 Million1.29% of portfolio
-
Highbridge Capital Management LLC New York, NY2.51MShares$928,5610.34% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.83MShares$678,0160.0% of portfolio
-
Tang Capital Management LLC San Diego, CA1.37MShares$508,4080.06% of portfolio
About BioAtla, Inc.
- Ticker BCAB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,304,100
- Market Cap $13.4M
- Description
- BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...